Q1 2025 Earnings Forecast for Zymeworks Inc. (NYSE:ZYME) Issued By HC Wainwright

Zymeworks Inc. (NYSE:ZYME) – Equities researchers at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Zymeworks in a research note issued on Wednesday, September 25th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.47) per share for the quarter, down from their prior estimate of ($0.45). HC Wainwright has a “Neutral” rating and a $12.00 price objective on the stock. The consensus estimate for Zymeworks’ current full-year earnings is ($0.85) per share. HC Wainwright also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.55) EPS and FY2025 earnings at ($2.05) EPS.

Separately, Stifel Nicolaus boosted their price objective on shares of Zymeworks from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd.

Zymeworks Trading Down 0.4 %

Shares of NYSE ZYME opened at $12.42 on Friday. Zymeworks has a 1-year low of $6.01 and a 1-year high of $13.27. The company has a 50-day moving average of $11.28 and a two-hundred day moving average of $9.94. The company has a market cap of $878.16 million, a PE ratio of -6.94 and a beta of 1.19.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. The business had revenue of $19.24 million for the quarter, compared to the consensus estimate of $23.16 million. Zymeworks had a negative net margin of 179.42% and a negative return on equity of 21.97%. During the same quarter in the prior year, the company earned ($0.76) EPS.

Institutional Trading of Zymeworks

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZYME. AlphaMark Advisors LLC bought a new stake in shares of Zymeworks during the 1st quarter valued at $32,000. Quest Partners LLC increased its holdings in Zymeworks by 8,049.6% in the second quarter. Quest Partners LLC now owns 9,209 shares of the company’s stock valued at $78,000 after purchasing an additional 9,096 shares during the last quarter. MQS Management LLC acquired a new position in Zymeworks in the second quarter valued at about $92,000. Arizona State Retirement System lifted its stake in Zymeworks by 11.1% in the second quarter. Arizona State Retirement System now owns 12,841 shares of the company’s stock valued at $109,000 after buying an additional 1,285 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new position in Zymeworks during the first quarter worth about $117,000. 92.89% of the stock is owned by institutional investors.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.